34
Participants
Start Date
August 24, 2017
Primary Completion Date
December 1, 2021
Study Completion Date
December 2, 2021
Nab-Rapamycin
Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m\^2; at Dose Level 2, 3-6 six patients will receive 75 mg/m\^2; and at Dose Level 3, 3-6 patients will receive 100 mg/m\^2.
Nivolumab
A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
Sarcoma Oncology Research Center, Santa Monica
Collaborators (1)
Aadi Bioscience, Inc.
INDUSTRY
Sarcoma Oncology Research Center, LLC
OTHER